Patents Assigned to APHP
-
Patent number: 10647752Abstract: The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.Type: GrantFiled: September 21, 2016Date of Patent: May 12, 2020Assignees: INSERM (Institut National de la Santé et de la Recherche Medicale), Fondation Imagine, Assistance Publique-Hopitaux de Paris (APHP), Université Paris Descartes, Centre National de la Recherche Scientifique (CNRS), Université de Bourgogne, CNAM—Conservatoire National des Arts at MetierInventors: Zakia Belaid-Choucair, Olivier Hermine, Matthieu Montes, Carmen Garrido-Fleury, Renaud Seigneuric, Guillaume Marcion
-
Patent number: 10646134Abstract: It is proposed a method for post-processing images of an region of interest in a subject, the images being acquired with a magnetic resonance imaging technique, the method for post-processing comprising at least the step of: —unwrapping the phase of each image, —extracting a complex signal over echo time for at least one pixel of the unwrapped images, and —calculating fat characterization parameters by using a fitting technique applied on a model, the model being a function which associates to a plurality of parameters each extracted complex signal, the plurality of parameters comprising at least two fat characterization parameters, the magnitude error and the phase error generated by the use of the bipolar readout gradients, the fitting technique being a non-linear least-square fitting technique using pseudo-random initial conditions.Type: GrantFiled: April 22, 2016Date of Patent: May 12, 2020Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7, UNIVERSITE VERSAILLES SAINT-QUENTIN-EN-YVELINES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)Inventors: Benjamin Leporq, Simon Lambert, Bernard Van Beers
-
Patent number: 10578619Abstract: The present invention relates to methods and kits for identifying effector regulatory T cells. In particular the present invention relates to use of CD15s as a biomarker for eTreg cells. The present invention also relates to a method for identifying effector Treg cells (eTreg) in a fluid sample comprising the steps of i) detecting the cell surface expression of CD4, CD25, CD127 and CD15s markers on the cell population contained in the fluid sample and ii) concluding that the cells expressing CD4, CD25, CD127 at low levels and CD15s are the effector Treg cells. The present invention also relates to a method for identifying effector Treg cells (eTreg) in a tissue sample comprising the steps of i) detecting the cell expression of CD4, CD25, Foxp3 and CD15s markers and ii) concluding that the cells expressing CD4, CD25, Foxp3 and CD15s are the effector Treg cells.Type: GrantFiled: July 30, 2014Date of Patent: March 3, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)Inventors: Guy Gorochov, Makoto Miyara
-
Patent number: 10563264Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: August 16, 2019Date of Patent: February 18, 2020Assignees: PML Screening, LLC, The Universite Paris-Sud, The Assistance Publique—Hopitaux de Paris (APHP), The Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Patent number: 10561840Abstract: The present invention relates to methods and devices to consolidate memory and/or cognitive functions by monitoring brain rhythms and delivering a stimulus at an appropriate stage of sleep cycle.Type: GrantFiled: December 22, 2015Date of Patent: February 18, 2020Assignees: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), APHP (ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), SORBONNE UNIVERSITE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Michel Le Van Quyen, Stéphane Charpier, Séverine Mahon
-
Patent number: 10556953Abstract: The present invention relates to a method for treating MI or AMI in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of an agent capable of depleting CD8 T cells. More particularly, this present invention relates to a method for treating acute myocardial infarction by reducing the size of necrosis and limiting 10 the post ischemic left ventricular remodeling.Type: GrantFiled: October 11, 2016Date of Patent: February 11, 2020Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (APHP)Inventor: Hafid Ait-Oufella
-
Patent number: 10548980Abstract: The present invention relates to pharmaceutical composition and uses thereof for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV). In particular, the present invention relates to a P2X7 receptor antagonist for use in a method of restoring T-cell lymphopoiesis in a subject infected with human immunodeficiency virus (HIV) comprising administering to the subject a therapeutically effective amount of said P2X7 receptor antagonist.Type: GrantFiled: January 13, 2017Date of Patent: February 4, 2020Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Université Paris-Est Créteil Val de Marne, Assistance Publique-Hôpitaux de Paris (APHP)Inventors: Yves Levy, Jean-Daniel Lelievre, Inna Menkova-Garnier
-
Patent number: 10544463Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: August 20, 2019Date of Patent: January 28, 2020Assignees: PML Screening, LLC, The Universite Paris-Sud, The Assistance Publique—Hopitaux de Paris (APHP), The Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Publication number: 20190381115Abstract: The present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.Type: ApplicationFiled: November 13, 2015Publication date: December 19, 2019Applicants: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP), ECOLE D'INGENIEURS DE PURPANInventors: Philippe LANGELLA, Sylvie MIQUEL, Rebeca MARTIN ROSIQUE, Luis BERMUDEZ HUMARAN, Muriel THOMAS, Harry SOKOL, Frédéric CARVALHO, Vassilia THEODOROU
-
Publication number: 20190366033Abstract: An in-ear stimulation system including a first device configured to be worn at least partially in a first ear canal of a subject and a second device configured to be worn at least partially in a second ear canal of the subject. Each of the first device and the second device includes: at least one in-ear active electrode configured to receive a bio-signal and at least one in-ear reference electrode configured to receive a bio-signal; at least one stimulation device configured for emitting at least one electrical or sensory stimulus; and an electronic system configured to detect at least one bio-signal pattern from the bio-signals measured from the electrodes.Type: ApplicationFiled: January 19, 2018Publication date: December 5, 2019Applicants: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SORBONNE UNIVERSITE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Michel LE VAN QUYEN, Alexis GENIN, Alexis STEINER, Mario VALDERRAMA, Miguel NAVARRETE
-
Publication number: 20190307738Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.Type: ApplicationFiled: June 13, 2017Publication date: October 10, 2019Applicants: Institut National de la Sante et de la Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS), Universite Paris SUD, Assistance Publique-Hopitaux de Paris (APHP), Hopital Marie LannelongueInventors: Sylvia COHEN-KAMINSKY, Marc HUMBERT, Sebastien DUMAS, Gilles BRU-MERCIER, Samir MESSAOUDI, Jean-Daniel BRION, Mouad ALAMI, Gilles GALVANI
-
Publication number: 20190242908Abstract: Inventors have shown that the protein isthmin-1 (ISM-1) is expressed at kidney level in animal and human model. They have also shown that this protein is expressed on the surface but also intracellular of the circulating leukocytes. They have observed that its expression is increased when a subject suffers from INS, MCN or FSGS compared to healthy controls. Among various causes of nephrotic syndrome, ISM-1 leucocyte expression is dramatically increased in patients with INS, MCN or FSGS. Accordingly, the present invention relates to a method for diagnosing INS, MCN or FSGS in a subject comprising the steps of: i) measuring the membrane expression level of isthmin-1 on the circulating leukocytes in a biological sample obtained from said subject; ii) comparing the expression level measured at step i) with its predetermined reference value, and iii) concluding that the subject suffers from INS, MCN or FSGS when the membrane expression level of isthmin-1 is higher than its predetermined reference value.Type: ApplicationFiled: September 7, 2017Publication date: August 8, 2019Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), SORBONNE UNIVERSITEInventor: Jean-Jacques BOFFA
-
Patent number: 10358469Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. In particular, the present invention relates to a polypeptide comprising or consisting of i) an amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1 or, ii) an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1, or iii) an amino acid sequence which is a retro-inverso of the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1 or, iv) an amino acid sequence which is retro-inverso of the amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1.Type: GrantFiled: February 17, 2015Date of Patent: July 23, 2019Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP)Inventors: Jean-Luc Poyet, Heriberto Bruzzoni-Giovanelli, Léonard Jagot-Lacoussiere
-
Patent number: 10337027Abstract: A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN).Type: GrantFiled: May 21, 2015Date of Patent: July 2, 2019Assignees: APHP (ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS), CORNELL UNIVERSITY, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE M, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS, UNIVERSITÉ DE STRASBOURGInventors: Helene Monique Puccio, Patrick Aubourg, Ronald G. Crystal, Pierre Bougneres
-
Patent number: 10322162Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of ischemic conditions. In particular, the present invention relates to a method of treating an ischemic condition in a subject in need thereof comprising administering the subject with a polypeptide comprising an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino acid residue at position 186 to the amino acid residue at position 406 in SEQ ID NO: 1.Type: GrantFiled: January 6, 2016Date of Patent: June 18, 2019Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), COLLEGE DE FRANCE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), ECOLE NATIONALE VETERINAIRE D'ALFORT (ENVA)Inventors: Stéphane Germain, Alain Berdeaux, Renaud Tissier, Bijan Ghaleh-Marzban, Catherine Monnot, Ariane Galaup
-
Publication number: 20190119652Abstract: The present invention relates to a bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone. The burden of STl31-025b:H4 Escherichia coli clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025b E. coli strains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes STI31-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs.Type: ApplicationFiled: April 12, 2017Publication date: April 25, 2019Applicants: NSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS DIDEROT - PARIS 7, INSTITUT PASTEUR, UNIVERSITÉ PARIS XIII PARIS-NORDInventors: Jean-Damien RICARD, Olivier CLERMONT, Laurent DEBARBIEUX, Erick DENAMUR, Nicolas DUFOUR
-
Patent number: 10240205Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: June 30, 2017Date of Patent: March 26, 2019Assignees: Population Bio, Inc., The Universite Paris-Sud, The Assistance Publique—Hopitaux de Paris (APHP), The Institut National de la Sante et de la Recherche Medicale (INSERM), PML Screening, LLCInventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Publication number: 20190022223Abstract: The present invention relates to pharmaceutical composition and uses thereof for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV). In particular, the present invention relates to a P2X7 receptor antagonist for use in a method of restoring T-cell lymphopoiesis in a subject infected with human immunodeficiency virus (HIV) comprising administering to the subject a therapeutically effective amount of said P2X7 receptor antagonist.Type: ApplicationFiled: January 13, 2017Publication date: January 24, 2019Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS-EST CRÉTEIL VAL DE MARNE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)Inventors: Yves LEVY, Jean-Daniel LELIEVRE, Inna MENKOVA-GARNIER
-
Patent number: 10183061Abstract: The present invention relates to the boosting of Treg cells for the treatment of Alzheimer's disease and related disorders.Type: GrantFiled: June 20, 2014Date of Patent: January 22, 2019Assignees: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE), APHP (ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (INSTITUT NATIONAL DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITEInventors: Guillaume Dorothee, Eliane Piaggio, Dylla Ait Ahmed, Pierre Aucouturier
-
Patent number: 10159684Abstract: The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof.Type: GrantFiled: June 8, 2017Date of Patent: December 25, 2018Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DESCARTES, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP)Inventors: Nicolette Farman, Frederic Jaisser, Francine Behar-Cohen, Selin Aractingi, Van Tuan Nguyen